Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech fireworks -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (1364)	12/17/2003 3:56:21 PM
From: Jibacoa	Read Replies (1) \| Respond to of 7424

ADVR is up 24.8% on volume of 4.368M about 1.5x its average.<g> It announced on Dec.9 that administration of its AVR118 in animals with induced EAE suppressed progression of this demyelinating neurological disease.(That serves as a potential model for the use of AVR118 in the treatment of MS.) "The positive results observed with AVR118 in the animal model emphasizes the broad potential for treatment of auto-immune diseases based on the anti-inflammatory properties of this novel drug," said Maribel de Diego, Ph.D., ADVR's head of immunology. "It is likely that the therapeutic activity of AVR118 in EAE is due to the drug's modulating effects on cytokines and chemokines. The strong effects of AVR118 in suppressing the progression of the demyelinating disease in the model in rats serve as an impetus for future clinical study of the possible therapeutic role for AVR118 in multiple sclerosis." bigcharts.marketwatch.com Bernard